AGX pricing follows the buying path enterprises actually need: a free read-only diagnostic, a fixed-scope paid pilot, then an annual contract only when recovered value, safety boundaries, and rollout scope are clear.
Each step has a clear purpose, output, and decision point. You do not move to the next step unless the evidence supports it.
A 1-2 week read-only review. AGX frames one revenue or margin problem, checks whether the evidence is usable, estimates the value at stake, and names the evidence gaps. Output: a leakage report and next-step recommendation.
A 4-8 week fixed-scope engagement. AGX tests recovery actions against historical cases, measures recovered value, tracks policy adherence, and produces an executive-ready evidence package before any production change.
Continuous revenue intelligence for approved workflows. AGX monitors evidence, prepares recovery actions, tracks outcomes, adapts when conditions change, and keeps owner approval and audit boundaries intact.
The diagnostic estimates the opportunity. The pilot tests whether recovery actions would have worked. The annual contract scales only where the value, cohort, owner boundary, and evidence quality are explicit.
Use the diagnostic to decide whether a pilot is worth funding. Use the pilot to decide whether an annual contract is justified.
A no-cost, read-only diagnostic that quantifies the likely leakage and tells you whether the evidence can support a paid pilot.
Start diagnosticA fixed-scope pilot that tests recovery actions on historical cases and measures whether the value is real before rollout.
Scope pilotOngoing revenue intelligence for approved workflows, with pricing tied to scale and validated economic value.
Discuss annual scopeThe diagnostic is free because its job is qualification: find the likely value, evidence quality, and whether a paid pilot is worth doing.
The paid pilot is fixed-scope and read-only. It does not change production systems, approve actions, or bypass owners.
Annual pricing is value-based but predictable: a base subscription, with optional capped upside tied to validated recovery or managed workflow scale.
The commercial path is designed to reduce buyer risk: diagnose for free, prove impact in a paid pilot, then scale only where the economics are clear.